The World Health Organization, national regulatory agencies and international pharmaceutical associations met in Russia to set standards for the manufacture of biologic and biosimiliar products in that country. A key focus is establishing definitions and regulations for biosimilars, which are not yet recognized as distinct products under Russian law.

Related Summaries